- Arvinas reported Q2 2026 revenue of $249.7 million and a net income of $169.4 million, successfully swinging to a profit driven by Pfizer collaboration revenue, the Rigel license agreement, and a $50.0 million FDA approval milestone for VEPPANU.
- Total operating expenses declined by $8.3 million to $85.6 million, primarily due to lower R&D spending, while cash, cash equivalents, and marketable securities totaled $567.9 million at June 30, 2026.
- The company's cash resources are projected to fund operations into the second half of 2028, with future performance depending on Rigel's execution, upcoming early-stage pipeline data, and ongoing cash management.
